Graduate Medical Education, Salah Foundation Children's Hospital at Broward Health Medical Center, Fort Lauderdale, Florida, USA.
Salah Foundation Children's Hospital at Broward Health Medical Center, Fort Lauderdale, Florida, USA.
JPEN J Parenter Enteral Nutr. 2021 May;45(4):844-847. doi: 10.1002/jpen.2003. Epub 2020 Sep 8.
Intestinal failure-associated liver disease (IFALD) can lead to increased morbidity and mortality in patients with intestinal failure (IF). We report the case of a premature infant born at 25 weeks' gestation at a neighboring facility that developed surgical necrotizing enterocolitis and secondary IF with 6 cm of small bowel remaining measured from the ligament of treitz with jejunocolonic anastomosis. The patient's course was complicated by IFALD and transferred to our intestinal rehabilitation program at 3 months of age. He was treated with SMOF lipid in reduced lipid dosages to prevent and treat IFALD, including cycling of parenteral nutrition, monitoring of the glucose infusion rate, and adjusting the micronutrient, trace elements, and aggressive enteral feeding. Omegaven had not yet been approved during the time of this case presentation. During the course of his treatment, he experienced normalization of his liver profile tests and progressed toward enteral autonomy.
肠衰竭相关肝病（IFALD）可导致肠衰竭（IF）患者的发病率和死亡率增加。我们报告了一例在临近机构出生的 25 周早产儿的病例，该患儿患有外科性坏死性小肠结肠炎，并继发 IF，从Treitz 韧带测量剩余 6 厘米小肠，行空肠结肠吻合术。患儿的病程复杂，出现 IFALD，并于 3 月龄时转入我院肠康复项目。他接受 SMOF 脂质治疗，减少脂质剂量，以预防和治疗 IFALD，包括肠外营养循环、监测葡萄糖输注率以及调整微量营养素、微量元素和积极的肠内喂养。在本例中，Omegaven 尚未获得批准。在治疗过程中，他的肝功能检查指标正常，逐渐实现肠内自主喂养。
